ĐÁNH GIÁ KẾT QUẢ HÓA TRỊ TÂN BỔ TRỢ PHÁC ĐỒ PACLITAXEL – CARBOPLATIN TRONG UNG THƯ BUỒNG TRỨNG GIAI ĐOẠN III - IV TẠI BỆNH VIỆN K

Abstract

Objectives: To identify the clinical,laboratory characteristics and evaluation of the results of neoadjuvant chemotherapy paclitaxel - carboplatin in stage III-IV ovarian cancer patient. Patients and methods: Prospective combined retrospective descriptip study. 69 patients diagnosed with stage III-IV ovarian cancer who received neoadjuvant chemotherapy with paclitaxel-carboplatin regimen at K hospital from 1/2018 – 4/2023. Research results: The mean age is 60,0 ± 8,4. The main presenting symptom is pelvic pain (85,5%), the main presenting sign is ascites (85,5%). Histopathology is mainly high-grade serous carcinoma (75,4%). Most patients have tumor size >5 cm (79,7%), CA125 concentration > 1000U/mL (55,1%). The most common sites of distant metastasis are pleura (20,3%), cervical lymph nodes (21,7%). The clinical response rate is 97,1%, the optimal surgery rate is 92,8%. The factor affecting the treatment response of the regimen was determined to be the histopathological. The most common adverse effects were leukopenia (24,6%) and mainly grade I-II. Conclusions: The regimen has good efficacy and relatively safe.